Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974323 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
A Phase 3 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 2,238
- Enrollment target
NCT01974323 is a Phase 3 study that has completed, run by Almirall, S.A.. The registered enrollment target is 2,238 participants.
The verdict
NCT01974323, a Phase 3 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,238 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
Interventions
- DRUG Dapsone Gel
- DRUG Dapsone Gel Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,238 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01974323
The ClinicalTrials.gov registry entry for NCT01974323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapsone Gel is the first listed.
NCT01974323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01974323 about?
NCT01974323 is a clinical study titled "Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris". This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
What is the current status of trial NCT01974323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,238 participants. The study started on 2013-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01974323?
The interventions under investigation include: Dapsone Gel (DRUG), Dapsone Gel Vehicle (DRUG).
Who is sponsoring clinical trial NCT01974323?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.